Do you have Acute Myeloid Leukemia (AML) and want to try a new study drug that might help treat your cancer?

The goal of this research study is to test a new study treatment for a specific type of stomach cancer. It is focused on people whose tumors are CLDN18.2 positive, PD-L1 positive, and HER2 negative. This new study treatment has 3 parts: 1. A study drug called zolbetuximab 2. Another study drug called pembrolizumab 3. Standard chemotherapy (mFOLFOX or CAPOX) Researchers want to know if this combination is safe and if it works better than current treatments for people living with this specific type of stomach cancer

Have you been diagnosed with GCB Subtype of Diffuse LargeB-cell Lymphoma (DLBCL)? If so, you may be able to take part in a research study looking at Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL

The purpose of this study is to look at combinations of medicines given after a stem cell transplant and see how well the combinations work to prevent graft versus host disease and infection.

The purpose is to compare the efficacy of zanidatamab plus chemotherapy versus trastuzumab plus chemotherapy

The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.